The Pharmacotherapy of Target Symptoms Associated with Autistic Disorder and Other Pervasive Developmental Disorders
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Research into the pharmacotherapy of autistic disorder has steadily increased over the past two decades. Several psychoactive medications have shown efficacy for selected symptoms of autistic disorder and can be used to augment critical educational and behavioral interventions that are the mainstays of treatment. A comprehensive review of medication trials conducted in individuals with autistic disorder and other pervasive developmental disorders is presented. The typical antipsychotic haloperidol is the best-studied medication in autistic disorder but is associated with a high rate of dyskinesias. Investigations to date suggest that the atypical antipsychotics such as risperidone have efficacy for certain symptoms of autistic disorder and may be better tolerated than typical antipsychotics. Preliminary results from trials with serotonin-reuptake inhibitors are favorable, although efficacy has not been demonstrated in younger age groups. Recent controlled studies of nalfrexone suggest that the drug has minimal efficacy. In two small controlled investigations, clonidine was more effective than placebo for a variety of symptoms, including hyperactivity and irritability; in one of these studies, however, the majority of patients relapsed within several months. Psychostimulants reduced hyperactivity and irritability in one small double-blind crossover study in children with autistic disorder, although these agents are frequently reported to exacerbate irritability, insomnia, and aggression in clinical populations. Recent controlled trials of secretin have not shown efficacy compared to placebo. Several other medications, including buspirone, mood stabilizers, and beta-blockers, have produced symptom reduction in some open-label studies and may warrant controlled investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnsten, A., Cai, J., & Goldman-Rakic, P. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-11-04287.1988 · Cited by 391
Clonidine Treatment of Hyperactive and Impulsive Children with Autistic Disorder
JASELSKIS, C. A., COOK, E. H., FLETCHER, K. E., & LEVENTHAL, B. L. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199210000-00005 · Cited by 328
Naltrexone in autistic children: Behavioral symptoms and attentional learning
CAMPBELL, M., ANDERSON, L. T., SMALL, A. M., ADAMS, P., GONZALEZ, N. M., & ERNST, M. (1993) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199311000-00024 · Cited by 210
Brief report: A double-blind study of naltrexone in infantile autism
Leboyer, M., Bouvard, M. P., Launay, J.-M., Tabuteau, F., Waller, D., Dugas, M., Kerdelhue, B., Lensing, P., & Panksepp, J. (1992) · Journal of Autism and Developmental Disorders · doi:10.1007/bf01058158 · Cited by 130
Buitelaar, J. K., van der Gaag, R. J., & van der Hoeven, J. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0203 · Cited by 113
Bouvard, M. P., Leboyer, M., Launay, J.-M., Recasens, C., Plumet, M.-H., Waller-Perotte, D., Tabuteau, F., Bondoux, D., Dugas, M., Lensing, P., et al. (1995) · Psychiatry Research · doi:10.1016/0165-1781(95)02601-r · Cited by 112
Naltrexone in autistic children: An acute open dose range tolerance trial
CAMPBELL, M., OVERALL, J. E., SMALL, A. M., SOKOL, M. S., SPENCER, E. K., ADAMS, P., FOLTZ, R. L., MONTI, K. M., PERRY, R., NOBLER, M., et al. (1989) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198903000-00009 · Cited by 93
Cited by
Management of Children With Autism Spectrum Disorders
Myers, S. M., Johnson, C. P., & the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2362 · Cited by 1,125
Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., & Dunbar, F. (2004) · Pediatrics · doi:10.1542/peds.2003-0264-f · Cited by 566
High Rates of Psychiatric Co-Morbidity in PDD-NOS
de Bruin, E. I., Ferdinand, R. F., Meester, S., de Nijs, P. F. A., & Verheij, F. (2007) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0215-x · Cited by 508
Serotonin and brain development: role in human developmental diseases
Whitaker-Azmitia, P. M. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00615-3 · Cited by 506
King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
“Together, the results of this trial highlight that SSRI exposure in children with ASDs is not without risk.(14,38-40) Ourplaceboresponserateof34.”
Result
Metadata
- Authors
- Posey, D. J., & McDougle, C. J.
- Venue
- Harvard Review of Psychiatry
- Published
- 2000-07
- Volume
- 8
- Issue
- 2
- Pages
- 45-63
- ISSN
- 1067-3229 (ISSN-L)
- OpenAlex
- W2083022671
- Cited by
- 105
- References
- 7
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.